about
Does household access to improved water and sanitation in infancy and childhood predict better vocabulary test performance in Ethiopian, Indian, Peruvian and Vietnamese cohort studies?Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa.Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment.Changes in second-line regimen durability and continuity of care in relation to national ART guideline changes in South AfricaTiming of pregnancy, postpartum risk of virologic failure and loss to follow-up among HIV-positive women.Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohortLost opportunities to complete CD4+ lymphocyte testing among patients who tested positive for HIV in South AfricaEarly loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South AfricaThe relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa.Poorer ART outcomes with increasing age at a large public sector HIV clinic in Johannesburg, South Africa.Systematic Differences between Cochrane and Non-Cochrane Meta-Analyses on the Same Topic: A Matched Pair Analysis.Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studiesRapid point-of-care CD4 testing at mobile HIV testing sites to increase linkage to care: an evaluation of a pilot program in South AfricaGender differences in mortality and CD4 count response among virally suppressed HIV-positive patients.Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir.Treatment outcomes of HIV-positive patients on first-line antiretroviral therapy in private versus public HIV clinics in Johannesburg, South AfricaCohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa.The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting.Rates and cost of hospitalization before and after initiation of antiretroviral therapy in urban and rural settings in South Africa.Outcomes of stable HIV-positive patients down-referred from a doctor-managed antiretroviral therapy clinic to a nurse-managed primary health clinic for monitoring and treatmentIncreases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South AfricaHas the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?Simplified clinical algorithm for identifying patients eligible for immediate initiation of antiretroviral therapy for HIV (SLATE): protocol for a randomised evaluation.Changes in elevated cholesterol in the era of tenofovir in South Africa: risk factors, clinical management and outcomes.Prioritizing health outcomes of HIV-exposed, uninfected children in low and middle-income countries: response to Powis et al.Mortality in the First 3 Months on Antiretroviral Therapy Among HIV-Positive Adults in Low- and Middle-income Countries: A Meta-analysis.Incident tuberculosis in HIV-positive children, adolescents and adults on antiretroviral therapy in South Africa.Prevalence and unmet need for diabetes care across the care continuum in a national sample of South African adults: Evidence from the SANHANES-1, 2011-2012Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.In-home HIV testing and nevirapine dosing by traditional birth attendants in rural Zambia: a feasibility study.A meta-analysis assessing all-cause mortality in HIV-exposed uninfected compared with HIV-unexposed uninfected infants and children.Cost and outcomes of paediatric antiretroviral treatment in South Africa.Changing the South African national antiretroviral therapy guidelines: The role of cost modelling.Regimen durability in HIV-infected children and adolescents initiating first-line ART in a large public sector HIV cohort in South Africa.Estimating retention in HIV care accounting for patient transfers: A national laboratory cohort study in South Africa.Causal language and strength of inference in academic and media articles shared in social media (CLAIMS): A systematic review.Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South AfricaImproved simplified clinical algorithm for identifying patients eligible for immediate initiation of antiretroviral therapy for HIV (SLATE II): protocol for a randomized evaluationCorrection: Estimating retention in HIV care accounting for patient transfers: A national laboratory cohort study in South Africa
P50
Q30378160-CDC59DB8-7EBB-41E2-BB19-7B6362BEB055Q33533887-D6776A61-D1FF-49B8-B0FE-6D179785BBA7Q33697770-399C8F95-0F7C-4EF1-9B93-43C987127A60Q33777513-D0FE7462-8B9E-4A2A-8B8E-A7D4ED4BD921Q33853679-78ECD92B-2849-47D2-8AA7-67E906190219Q33979490-5806A373-043A-4F63-9840-D7FFF18043F1Q34092731-7194853E-A54F-480B-A8C5-6155DB790D52Q34196503-E8C6D90C-D783-4C46-B950-CDE8ADA2AE38Q34433397-F17C61BA-38B3-4902-8770-A0838AA999D0Q34451025-9EC0E54A-4F89-4FD6-87A9-A7D42AA063C1Q35737660-683F1046-15B0-46E9-AF91-2A82B955E4E5Q35869658-D845CAC3-D57C-430A-A5C5-CBF16439D408Q36204098-F38DEF7C-2C86-42B0-9C88-5F1501759BA8Q36279351-B9A6DD91-C39E-4988-B838-5F54B64186AAQ36629441-71F0DC19-1E5A-4D00-91D0-6AE537A46074Q36651106-4D0DF4C7-7606-40A3-B0C0-0609BE8A190EQ36729112-5ECAA808-F88A-4D39-BC66-D00BCECA38DCQ36749434-51574101-04DF-43A8-9227-6D31971E39FAQ36763062-5F5FBF60-0403-47DF-A0E3-A93988D12BBDQ36763727-00B08283-77EF-49C5-AB50-568DB86CFB31Q36893283-38C73465-5C9C-480D-91C3-0F25C29D3152Q37330398-05DEC581-272B-4725-9BDC-F0D9B35159C2Q38404966-C997057B-58C5-45D2-9EB6-21B1F2F64FF7Q39336810-A251510D-8D76-4C82-9985-7523E7FFEBF1Q40278973-A2D3E274-3D28-4D8D-A399-729ABFA30178Q40413833-989D641B-9B08-49D6-991F-BA3D7AFA27D0Q40579899-2EB4CFA0-8B82-496E-9D04-DDBF5481195FQ40620262-86F0A46D-8E9D-4589-BBDA-E8B0F6D63A0CQ41992289-56958A00-4F27-4619-A9E6-9EC88F4E1AE6Q42234057-D212C342-86AD-4666-A82E-FD4C3BA3EF15Q42245051-A5F6B86D-BF45-480E-BF93-498384DDFE6AQ46307630-0D179ED3-25AF-4D0A-9F3E-5298F25E9C8DQ46487268-6636C8C2-99AB-445F-B136-7E8813515016Q46736922-6DFAA0D5-0385-4E59-90DD-D9C5C24BAC84Q52587803-CF2140E4-FDE0-4DF0-94FA-9BF64F6B5610Q55205473-026DAD1C-6C3E-4541-B565-966CF08B91F7Q55410258-38834D9E-C2DF-4368-98C7-88FA98CB2024Q57040953-4217DECB-92AB-4632-8CE6-8781B319948BQ57282181-6E4E1D35-E405-4751-B378-26EE82A90896Q58791345-1DB3E4D9-4874-4079-942D-A3F49BBA00BB
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alana Brennan
@ast
Alana Brennan
@en
Alana Brennan
@es
Alana Brennan
@nl
Alana Brennan
@sl
type
label
Alana Brennan
@ast
Alana Brennan
@en
Alana Brennan
@es
Alana Brennan
@nl
Alana Brennan
@sl
prefLabel
Alana Brennan
@ast
Alana Brennan
@en
Alana Brennan
@es
Alana Brennan
@nl
Alana Brennan
@sl
P106
P21
P31
P496
0000-0002-7746-0668